英国剑桥肿瘤DNA损伤博士后职位招聘

Postdoctoral Long Title: Extending the range of olaparib-treatable cancers by targeting the UBE2D-RNF138 ubiquitylation axis important for homologous recombination repair

We're currently looking for talented scientists to join our innovative academic-style Postdoc program. From our centre in Chesterford Research Park, Cambridge, UK, you'll be in a global pharma ceutical environment, contributing to live projects right from the start. You'll take part in a comprehensive training programme, including a focus on drug discovery and development, given access to our existing Postdoctoral research, and encouraged to pursue your own independent research in cutting edge laboratories. It's a newly expanding programme spanning a range of therapeutic areas across a wide range of disciplines.

What's more, you'll have the support of a leading academic advisor, who'll provide you with the guidance and knowledge you need to develop your career. This is an exciting area that hasn't been explored to its full potential, making this an opportunity to make a real difference to the future of medical science.

AstraZeneca (AZ) is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescript ion medicines for some of the world's most serious diseases. But we're more than one of the world's leading pharmaceutical companies. At AZ, we're proud to have a unique workplace culture that inspires innovation and collaboration. Here, employees are empowered to express diverse perspectives – and are made to feel valued, energised and rewarded for their ideas and creativity

You will have the unique opportunity of being part of the Oncology function of AZ, the world leader company in DNA-damage response (DDR) inhibitors. The project has the potential to identify new targets for drug intervention with the aim of potentiating the activity of the PARP inhibitor olaparib/Lynparza© both in non-BRCA mutated and BRCA-mutated olaparib-resistant genetic backgrounds.

The project is a close collaboration with the laboratory of Dr. Christine Schmidt (Genome Stability Lab), an expert in the DDR and ubiquitin signalling at the University of Manchester. Your research will take place at AZ in the Chesterford Research Park in Cambridge, where the Bioscience DDR team is located, and you will benefit from supervision from both the academic laboratory and the AZ DDR Bioscience team. You will also have the opportunity to work and interact with our global DDR team and expand your skillset using various cutting-edge technologies.

You will acquire fundamentals of drug discovery and development and be exposed to the reality of patient-focused research. The breadth and depth of expertise across the AZ community with outstanding external collaborations will support you in producing high impact work that you will have the opportunity to publish and present to the external international scientific community.

Essential Education and Exp erience required:

PhD in molecular and cell biology preferentially in the DNA-damage response field.

Oncology knowledge with an understanding of cellular signalling.

Proven ability to independently design and execute incisive experiments and interpret results.

A strong scientific track-record, as evidenced by published or accepted papers in well recognized peer-reviewed journals, oral and/or poster presentations at scientific meetings.

Desirable:

Experience in a range of in vitro biochemical, cell biology and pharmacology-related skills that can be applied to DDR and oncology research. Examples of these are growth inhibition/toxicity assays, immunoblotting, high-content biology and foci or live-cell imaging, cell cycle analysis, flow cytometry, comet and/or genotoxicity assays, CRISPR cell line models, DNA repair efficiency reporter assays.

Experience in mouse work, including xenografts.

Strong interpersonal, organizational and communication skills.

Strong passion & commitment to science, and ability to work well within a group/team environment.

Skills and Capabilities required:

Using a range of pre-clinical models to explore DNA damage response biology, from in vitro cell line culture to in vivo mouse xenografts.

Ability to work in multidisciplinary teams, as the work plan includes both in vitro cell line and in vivo mouse work.

This is a 3-year programme. 2 years will be a Fixed Term Contract, with a 1 year extension which will be merit based. The role will be based at the Bioscience DDR team at the Chesterford Research Park in Cambridge with a competitive salary on offer. To apply for this position, please click the apply link below.

Advert opening date – 5th March 2018 / Advert closing date – 13th May 2018

AZ welcomes applications from all sections of the community. AZ is an equal opportunity employer. AZ will consider all qualified applicants for employment without discrimination on grounds of disability, sex or sexual orientation, pregnancy or maternity leave status, race or national or ethnic origin, age, religion or belief, gender identity or re-assignment, marital or civil partnership status, protected veteran status (if applicable) or any other characteristic protected by law.

If you share our passion for scientific excellence, find out more at; https://careers.astrazeneca.com/students/programmes/post-doctoral-programmes